MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, JSPR had -$42,945K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$42,945K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Other income, net
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Change in fair value of warrant ...
    • Accrued expenses and other curre...
    • Prepaid expenses and other curre...
    • Others

Cash Flow
2025-12-31
Total operating expense
83,883
Other income, net
8,082
Net loss
-75,801
Depreciation and amortization expense
1,056
Impairment of long-lived assets
1,112
Non-cash lease expense
1,164
Stock-based compensation expense
6,713
Change in fair value of warrant liability
-8,528
Offering costs recognized in other expense, net
2,046
Prepaid expenses and other current assets
1,779
Other non-current assets
-707
Accounts payable
2,193
Accrued expenses and other current liabilities
-4,374
Operating lease liability
-1,670
Net cash used in operating activities
-77,161
Purchases of property and equipment
7
Proceeds from sales of property and equipment
12
Net cash provided by (used in) investing activities
5
Proceeds from issuance of common stock through atm offering, net
6,454
Proceeds from issuance of common stock and warrants through underwritten offering, net
27,514
Proceeds from issuance of common stock pursuant to employee stock purchase plan
243
Net cash provided by financing activities
34,211
Net decrease in cash, cash equivalents and restricted cash
-42,945
Cash, cash equivalents and restricted cash at beginning of the year
72,054
Cash, cash equivalents and restricted cash at end of the year
29,109
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock and...$27,514K Proceeds from issuance ofcommon stock through...$6,454K Proceeds from issuance ofcommon stock pursuant...$243K Proceeds from sales ofproperty and equipment$12K Net cash provided byfinancing activities$34,211K Net cash provided by(used in) investing...$5K Canceled cashflow$7K Net decrease incash, cash...-$42,945K Canceled cashflow$34,216K Stock-based compensationexpense$6,713K Accounts payable$2,193K Offering costsrecognized in other...$2,046K Non-cash lease expense$1,164K Impairment of long-livedassets$1,112K Depreciation andamortization expense$1,056K Other non-currentassets-$707K Purchases of property andequipment$7K Net cash used inoperating activities-$77,161K Canceled cashflow$14,991K Other income, net$8,082K Net loss-$75,801K Change in fair value ofwarrant liability-$8,528K Canceled cashflow$8,082K Accrued expenses andother current...-$4,374K Prepaid expenses andother current assets$1,779K Operating lease liability-$1,670K Total operatingexpense$83,883K

Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics, Inc. (JSPR)